Spring Bank Pharmaceuticals (NASDAQ:SBPH) issued its quarterly earnings results on Monday. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.17, Morningstar.com reports.
NASDAQ:SBPH traded up $0.20 during mid-day trading on Tuesday, reaching $10.40. The company’s stock had a trading volume of 1 shares, compared to its average volume of 15,653. The firm has a market cap of $162.86 million, a price-to-earnings ratio of -5.67 and a beta of 0.84. Spring Bank Pharmaceuticals has a twelve month low of $8.14 and a twelve month high of $15.95.
A number of brokerages have issued reports on SBPH. Chardan Capital set a $45.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 30th. Cantor Fitzgerald set a $34.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $33.00.
TRADEMARK VIOLATION WARNING: “Spring Bank Pharmaceuticals (SBPH) Issues Earnings Results” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://dakotafinancialnews.com/2019/03/12/spring-bank-pharmaceuticals-sbph-issues-earnings-results.html.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
Featured Story: When is a capital gain realized?
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.